



## Exosomes in Tumor

Guest Editors:

### Dr. Sandra E. Ghayad

Center for CardioVascular and  
Nutrition Research (C2VN),  
INSERM 1263, INRAE 1260, Aix-  
Marseille University, 13385  
Marseille, France

### Dr. Nader Hussein

Cancer Research Center, CRCL  
(Centre de Recherche en  
Cancérologie de Lyon), Lyon,  
France

Deadline for manuscript  
submissions:

**closed (24 June 2024)**

## Message from the Guest Editors

Exosomes, small vesicles released by various cells, including cancer cells, carry a diverse cargo of proteins, lipids, and nucleic acids, which can be transferred to recipient cells, thereby influencing their behavior. They play a pivotal role in shaping the tumor microenvironment by contributing to promoting tumor–stroma crosstalk, angiogenesis, immune modulation, tumor-induced immune suppression, tumor growth, invasion, metastasis, and drug resistance.

Exosomes also hold immense diagnostic potential, serving as non-invasive biomarkers for cancer detection, prognosis, and treatment response assessment through liquid biopsies. Targeting exosomal cargo to inhibit tumor growth and modulate tumor-promoting signals shows potential for the development of novel anti-cancer strategies. Additionally, engineered exosomes offer a promising platform for targeted cancer therapy, delivering therapeutic agents to tumor cells while minimizing off-target effects and enhancing treatment efficacy.

This Special Issue welcomes original research articles and timely reviews on all aspects of exosomes that will open up new research avenues for precision oncology.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)